8-K - Actuate Therapeutics Inc | StockGist

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On November 28, 2025, Actuate Therapeutics, Inc. (the “Company”) entered into an At the Market Issuance Sales Agreem

Material Agreement

$100.0M

9.01

Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed with this report: Exhibit Number Exhibit Description Method of Filing 1.1 At th

Exhibits Only

Exhibits (3)

1.1

AT THE MARKET ISSUANCE SALES AGREEMENT

5.1

OPINION OF GREENBERG TRAURIG, LLP

8-K

CURRENT REPORT